Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from NLS Pharmaceutics ( (NLSP) ).
On July 18, 2025, NLS Pharmaceutics Ltd. announced the signing of a sixth amendment to its merger agreement with Kadimastem Ltd. and NLS Pharmaceutics (Israel) Ltd. This amendment clarifies the timing for calculating the exchange ratio and the number of shares to be issued in the merger. The companies are committed to completing the merger process diligently, aligning efforts to meet regulatory requirements and shareholder approvals.
More about NLS Pharmaceutics
NLS Pharmaceutics Ltd. is a Swiss-based pharmaceutical company focused on developing therapies for rare and complex central nervous system disorders. The company is engaged in research and development to bring innovative treatments to market, with a particular emphasis on addressing unmet medical needs.
Average Trading Volume: 298,810
Technical Sentiment Signal: Sell
Current Market Cap: $8.09M
For an in-depth examination of NLSP stock, go to TipRanks’ Overview page.